Johnson & Johnson Q3 net earnings fall 96% to $210 million; sales rise 6% to $25.4 billion

Bitget2026/10/13 10:22

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Johnson & Johnson posted Q3 2026 net earnings of USD 210 million, swinging from profit a year earlier.
Reported sales rose 6% to USD 25.4 billion versus Q3 2025.
Innovative Medicine net sales climbed 8% to USD 16.76 billion, while MedTech net sales increased to USD 8.64 billion.
CEO Joaquín Duato cited “accelerating momentum” and highlighted OTTAVA progress and positive Phase 3 multiple myeloma results.
2026 reported sales guidance increased to USD 101.0 billion–USD 101.4 billion, with adjusted EPS guidance lifted to USD 11.05–USD 11.15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20261013290017) on October 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Johnson & Johnson Q3 net earnings fall 96% to $210 million; sales rise 6% to $25.4 billion

You may also like

Crypto prices